From ME Research UK.
Prof. David Patrick
School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, USA
In many cases, the drugs used to treat various diseases are effective in only a proportion of patients. It can therefore be valuable to identify these individuals, so that those unlikely to benefit can be spared unnecessary treatments and potential side-effects.
Rituximab is an antibody that attacks B-lymphocytes, a type of white blood cell. The drug has been used to treat some cancers and autoimmune disorders, and a scientific report in 2011, by Øystein Fluge and Olav Mella of the Haukeland University Hospital in Bergen, suggested that the symptoms of ME/CFS could be improved by treatment with rituximab.
To read the rest of this story, click on the link below: